Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Oncology Therapies
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -47.32% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -47.32% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 31/12/96 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 31/03/17 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 16/05/21 |
Rajesh Krishnan
CTO | Chief Tech/Sci/R&D Officer | 51 | 27/08/19 |
Pablo Urbaneja
PRN | Corporate Officer/Principal | - | 30/06/21 |
Anita Wiseth
HRO | Human Resources Officer | - | 28/02/21 |
Chase Leavitt
LAW | General Counsel | 42 | 11/04/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 31/12/96 |
Dan Kisner
BRD | Director/Board Member | 77 | 06/06/19 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 26/01/21 |
James Breitmeyer
FOU | Founder | 70 | 31/12/96 |
William LaRue
BRD | Director/Board Member | 73 | 30/11/17 |
Michael Carter
BRD | Director/Board Member | 86 | 06/06/19 |
Charles Theuer
BRD | Director/Board Member | 60 | 30/04/18 |
Jill DeSimone
BRD | Director/Board Member | 68 | 02/01/23 |
Robert Wills
BRD | Director/Board Member | 70 | 06/06/19 |
Xin Nakanishi
BRD | Director/Board Member | 62 | 31/10/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,959,645 | 2,686,463 ( 90.77 %) | 0 | 90.77 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+23.33% | 47.02B | |
+49.45% | 41.86B | |
-0.15% | 41.76B | |
-4.27% | 28.8B | |
+12.42% | 26.05B | |
-21.52% | 19.15B | |
+4.20% | 12.55B | |
+29.75% | 12.34B | |
-4.18% | 11.82B |